The purpose of this Notice of Special Interest (NOSI) is to inform potential applicants about an area of special interest to NIAID on early phase translational research that will generate new malaria vaccine candidates with desirable features suitable for further downstream development and clinical evaluation. This NOSI encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially Plasmodium falciparum and Plasmodium vivax.

This NOSI is intended to encourage research to identify, characterize, credential and validate new protective antigens or vaccine candidates with appropriate assay systems or animal models. For purposes of this NOSI, protective antigens or vaccine candidates should demonstrate appropriate functional characteristics, such as prevention of infection, amelioration of disease, interruption of transmission, or prevention of relapse, or other functional features, when applicable.

This notice applies to application receipt dates on or after February 5, 2022 and subsequent receipt dates through January 7, 2025.

NOT-AI-22-014